High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.
Ravenhill, Benjamin J
Fielding, Ceri A
Wang, Eddie CY
Huttlin, Edward L
Davison, Andrew J
Wilkinson, Gavin WG
Stanton, Richard J
Weekes, Michael P
Cell Host Microbe
MetadataShow full item record
Nightingale, K., Lin, K., Ravenhill, B. J., Davies, C., Nobre, L., Fielding, C. A., Ruckova, E., et al. (2018). High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.. Cell Host Microbe, 24 (3), 447-460.e11. https://doi.org/10.1016/j.chom.2018.07.011
Human cytomegalovirus (HCMV) is an important pathogen with multiple immune evasion strategies, including virally facilitated degradation of host antiviral restriction factors. Here, we describe a multiplexed approach to discover proteins with innate immune function on the basis of active degradation by the proteasome or lysosome during early-phase HCMV infection. Using three orthogonal proteomic/transcriptomic screens to quantify protein degradation, with high confidence we identified 35 proteins enriched in antiviral restriction factors. A final screen employed a comprehensive panel of viral mutants to predict viral genes that target >250 human proteins. This approach revealed that helicase-like transcription factor (HLTF), a DNA helicase important in DNA repair, potently inhibits early viral gene expression but is rapidly degraded during infection. The functionally unknown HCMV protein UL145 facilitates HLTF degradation by recruiting the Cullin4 E3 ligase complex. Our approach and data will enable further identifications of innate pathways targeted by HCMV and other viruses.
Humans, Cytomegalovirus, Cytomegalovirus Infections, Proteins, DNA-Binding Proteins, Transcription Factors, Viral Proteins, Proteomics, Protein Stability, Immune Evasion
This work was supported by a Wellcome Trust Senior Clinical Research Fellowship (108070) to MPW, a strategic award to Cambridge Institute for Medical Research from the Wellcome Trust (100140), MRC Project Grants to GWGW, PT, ECYW and RJS (MR/L018373/1, MR/P001602/1), a Wellcome Trust Programme Grant (WT090323MA) to GWGW, ECYW and PT, and an MRC Programme Grant (MC_UU_12014/3) to AJD. This study was additionally supported by the Cambridge Biomedical Research Centre, UK.
Wellcome Trust (108070/Z/15/Z)
Wellcome Trust (100140/Z/12/Z)
External DOI: https://doi.org/10.1016/j.chom.2018.07.011
This record's URL: https://www.repository.cam.ac.uk/handle/1810/284578
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/